Investor Presentation - First Six Months of 2021

57 Investor presentation First six months of 2021 Novo Nordisk® Across the STEP 1, 3, and 4 trials, a weight loss of 16.9% to 18.2% was reported for people treated with semaglutide 2.4 mg STEP 1 Weight management Baseline body weight 105.3 Change from baseline in BW (%) STEP 3 Weight mgmt. STEP 4 Sustained weight management with IBT STEP 5 Weight loss over 2 years STEP 2 Weight mgmt. with T2D STEP 8 Head-to-head trial versus liraglutide 3.0 mg After 68 weeks After 20 weeks 105.8 107.2 96.1 106.0 99.8 104.5 Sema Placebo Sema IBT Sema Placebo Sema + IBT Placebo Sema 6.5 Placebo Sema Placebo Sema Lira 3.0 mg Placebo -2 -4 -6 -8 864202 +6∞ -2.4 -5.0 -5.2 -10 -8.8 -12 -14 -16 -18 -16.9* -17.6* -18.2* -16.7* -0.6 -3.1 -6.6 -10.6* * P-value <0.0001, based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies IBT: Intensive behavioural therapy; Sema: Semaglutide; Lira: Liraglutide; BW: Body weight; T2D: Type 2 diabetes; Mgmt.: Management * -17.1 -1.8

View entire presentation